News

With this acquisition, Laboratoires Thea is planning to strengthen its geographical presence by establishing new affiliates in countries where the company’s products were either sold through distributors or

GBR401 has been developed completely in-house by Glenmark‘s Biologics Research Centre located in Switzerland, using an advanced technology. GBR 401 targets lymphomas, leukemia’s of B-cell origin and inflammatory

to-BBB is planning to initiate the Phase I/II clinical trial in a few months at three academic hospitals in the Netherlands led by neuro-oncology experts of the Antoni

ANAVEX 2-73 is a new class of oral, disease-modifying drug being studied to potentially treat alzheimer’s disease itself, versus treating its symptoms. The Phase 1 study will evaluate

BioMAP offers insight into human pharmacological and toxicological properties of compounds, including on- and off-target effects, dose responses, and the discrimination of closely related compounds. The Patent no.

The study, a 48-week, global, double-blind, randomized, placebo-controlled trial, involved nearly 300 previously untreated patients infected with the most common form of hepatitis C virus (HCV), the genotype

REALIZE is the final of three clinical trials conducted as part of a global Phase 3 registration program for telaprevir in treatment-naïve and treatment-failure patients with chronic HCV

OMS103HP did not meet the pre-specified endpoints of these studies. No conclusions were made regarding the drug-effect due to confounding factors in the studies. Omeros chairman and chief

The randomised, double-blind, placebo-controlled, parallel-group, multi-centre Phase III study will evaluate the safety and efficacy dexpramipexole in people with familial or sporadic ALS. The study will enroll approximately